Lifeward Ltd. Reports First Quarter 2025 Financial Results
- Gross margin significantly improved to 42.2% from 26.4% year-over-year
- AlterG products revenue grew 17% to $3.3 million
- Operating loss reduced to $4.9M from $6.5M year-over-year
- First approval from major U.S. commercial health insurance for ReWalk 7
- New partnership with CorLife for workers' compensation market expansion
- Agreement with BARMER adds 8.5 million covered lives in Germany
- Overall revenue declined to $5.0M from $5.3M year-over-year
- ReWalk Exoskeletons revenue decreased by $0.8M compared to Q1 2024
- Cash position limited at $5.7M with highest quarterly cash burn in Q1
- Company needed to raise additional $0.5M through ATM facility post-quarter
Insights
Lifeward shows mixed Q1 results with revenue down 6%, but improving margins and lower operating expenses signal operational progress.
Lifeward reported
The company's gross margin showed significant improvement, increasing to
Operating expenses decreased to
The net loss improved to
Liquidity remains a concern with
Despite the revenue decline, several positive business developments show potential for future growth. These include the launch of ReWalk 7, the first approval by a major U.S. commercial insurer for ReWalk 7 coverage, a new partnership with CorLife for workers' compensation distribution, expanded MYOLYN partnership for FES cycling systems, and an agreement with BARMER in Germany to streamline access for 8.5 million potential beneficiaries. Management also highlighted improved Medicare claims processing and documentation clarity, which should accelerate future reimbursements.
For full-year 2025, Lifeward maintained its revenue guidance of
U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process
Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend
Second consecutive quarter of AlterG revenue growth over
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025.
Recent Highlights and Accomplishments for Lifeward
- Launched the ReWalk 7, the newest generation of personal exoskeleton, in the U.S. market following FDA clearance in March.
- Achieved first approval of a claim by a major U.S. commercial health insurance company for payment of a ReWalk 7 Personal Exoskeleton, marking a significant inflection point as Lifeward works to expand coverage beyond Medicare to the commercial health insurance segment.
- Established a new partnership with CorLife, a division of NuMotion, a healthcare services provider and benefits coordinator, for CorLife to exclusively distribute the ReWalk Personal Exoskeleton to individuals with workers’ compensation claims, which the Company expects will achieve greater growth and penetration into the workers’ compensation market for exoskeletons.
- Expanded the partnership with MYOLYN to broaden Lifeward’s distribution rights of the MyoCycle FES Cycling Therapy System to include referral sales for home use applications, the largest market segment for functional electrical stimulation (“FES”) cycles.
- Signed an agreement with BARMER, Germany’s second largest statutory health insurance company, to streamline access to ReWalk Personal Exoskeletons for eligible beneficiaries, adding 8.5 million covered lives in Germany.
“During the first quarter of 2025, we experienced improvement in the throughput of Medicare claims submissions as a greater number of qualified leads moved towards the final stages of claims preparation,” said Larry Jasinski, Chief Executive Officer. “We also gained greater clarity on the documentation requirements for Medicare claims from the Medicare Administrative Contractors who process them, which we expect to result in shorter cycle time for approval and payment of future claims.”
First Quarter 2025 Financial Results
Revenue was
Gross margin was
Operating expenses in the first quarter of 2025 were
Operating loss in the first quarter of 2025 was
Net loss was
Liquidity
As of March 31, 2025, Lifeward had
2025 Financial Guidance
For 2025, Lifeward continues to expect full year revenue in the range of
Conference Call
Lifeward management will host its conference call as follows:
| Date | May 15, 2025 | |
| Time | 8:30 AM EST | |
| Telephone | U.S: | 1-833-316-0561 |
| International: | 1-412-317-0690 | |
| Israel: | 1-80-9212373 | |
| Germany: | 0800-6647650 | |
| Access code | Please reference the “Lifeward Earnings Call” | |
| Webcast (live, listen-only and archive) | https://edge.media-server.com/mmc/p/5e35v6wk | |
The archived webcast will be available via the following https://edge.media-server.com/mmc/p/5e35v6wk or through the “Investors” section on our website at GoLifeward.com.
About Lifeward
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the ReStore Exo-Suit, and the MyoCycle FES System.
Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.
Lifeward®, ReWalk®, ReStore®, and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company’s ability to continue to operate as a going concern; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2024 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), the Company believes that the use of non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers to as non-GAAP financial measures, are not prepared in accordance with GAAP.
Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company’s non-cash expenses, the Company believes that providing non-GAAP financial measures that exclude non-cash share-based compensation expense and acquisition costs allows for more meaningful comparisons between operating results from period to period. Each of the Company’s non-GAAP financial measures is an important tool for financial and operational decision-making and for the Company’s evaluation of its operating results over different periods of time. The non-GAAP financial data are not measures of the Company’s financial performance under U.S. GAAP and should not be considered as alternatives to operating loss or net loss or any other performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in Lifeward’s industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on the Company’s reported financial results. Further, share-based compensation expense has been, and will continue for the foreseeable future, to be a significant recurring expense in the Company’s business and an important part of the compensation provided to its employees.
The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Lifeward urges investors to review the reconciliation of the Company’s non-GAAP financial measures to the comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate the Company’s business.
Lifeward does not provide GAAP reconciliation of its non-GAAP financial guidance because the Company is unable to predict with reasonable certainty and without unreasonable effort items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition-related expense, and earnout expense. The timing and amounts of these items are uncertain and could be material to Lifeward’s results computed in accordance with GAAP.
Lifeward Media Relations:
Kathleen O’Donnell
Vice President, Marketing & New Business Development
Lifeward Ltd.
E: media@golifeward.com
Lifeward Investor Contact:
Mike Lawless
Chief Financial Officer
Lifeward Ltd.
E: ir@golifeward.com
| Lifeward Ltd. And subsidiaries | |||||||||
| Condensed Consolidated Statements of Operations | |||||||||
| (Unaudited) | |||||||||
| (In thousands, except share and per share data) | |||||||||
| Three Months Ended | |||||||||
| March 31, | |||||||||
| 2025 | 2024 | ||||||||
| Revenue | $ | 5,034 | $ | 5,283 | |||||
| Cost of revenues | 2,912 | 3,888 | |||||||
| Gross profit | 2,122 | 1,395 | |||||||
| Operating expenses: | |||||||||
| Research and development, net | 918 | 1,291 | |||||||
| Sales and marketing | 3,837 | 5,014 | |||||||
| General and administrative | 2,220 | 1,592 | |||||||
| Total operating expenses | 6,975 | 7,897 | |||||||
| Operating loss | (4,853 | ) | (6,502 | ) | |||||
| Financial income, net | 30 | 232 | |||||||
| Loss before income taxes | (4,823 | ) | (6,270 | ) | |||||
| Taxes on income | 11 | 6 | |||||||
| Net loss | $ | (4,834 | ) | $ | (6,276 | ) | |||
| Basic net loss per ordinary share | $ | (0.46 | ) | $ | (0.73 | ) | |||
| Weighted average number of shares used in computing net loss per ordinary share basic and diluted | 10,486,151 | 8,590,088 | |||||||
| Lifeward Ltd. And subsidiaries | |||||||||
| Condensed Consolidated Balance Sheets | |||||||||
| (In thousands) | |||||||||
| (Unaudited) | (Audited) | ||||||||
| March 31, | December 31, | ||||||||
| 2025 | 2024 | ||||||||
| Assets | |||||||||
| Current assets | |||||||||
| Cash and cash equivalents | $ | 5,728 | $ | 6,746 | |||||
| Restricted Cash | 194 | 197 | |||||||
| Trade receivables, net of credit losses of | 5,165 | 6,004 | |||||||
| Prepaid expenses and other current assets | 1,929 | 1,624 | |||||||
| Inventories | 6,802 | 6,723 | |||||||
| Total current assets | 19,818 | 21,294 | |||||||
| Restricted cash and other long term assets | 219 | 240 | |||||||
| Operating lease right-of-use assets | 457 | 548 | |||||||
| Property and equipment, net | 777 | 867 | |||||||
| Goodwill | 7,538 | 7,538 | |||||||
| Total assets | $ | 28,809 | $ | 30,487 | |||||
| Liabilities and equity | |||||||||
| Current liabilities | |||||||||
| Trade payables | 4,466 | 5,022 | |||||||
| Current maturities of operating leases | 571 | 858 | |||||||
| Other current liabilities | 3,426 | 3,737 | |||||||
| Earnout liability | 608 | 608 | |||||||
| Total current liabilities | 9,071 | 10,225 | |||||||
| Non-current operating leases | 48 | 22 | |||||||
| Other long-term liabilities | 1,234 | 1,391 | |||||||
| Shareholders’ equity | 18,456 | 18,849 | |||||||
| Total liabilities and equity | $ | 28,809 | $ | 30,487 | |||||
| Lifeward Ltd. And subsidiaries | |||||||||
| Condensed Consolidated Statements of Cash Flows | |||||||||
| (Unaudited) | |||||||||
| (In thousands) | |||||||||
| Three Months Ended | |||||||||
| March 31, | |||||||||
| 2025 | 2024 | ||||||||
| Net Cash used in operating activities | $ | (5,493 | ) | $ | (7,673 | ) | |||
| Net Cash used in investing activities | (5 | ) | - | ||||||
| Net Cash provided by financing activities | 4,471 | - | |||||||
| Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash | 7 | (15 | ) | ||||||
| Decrease in cash, cash equivalents, and restricted cash | (1,020 | ) | (7,688 | ) | |||||
| Cash, cash equivalents, and restricted cash at beginning of period | 7,108 | 28,792 | |||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 6,088 | $ | 21,104 | |||||
| Lifeward Ltd. And subsidiaries | |||||||||
| (Unaudited) | |||||||||
| (In thousand) | |||||||||
| Three Months Ended | |||||||||
| March 31, | |||||||||
| 2025 | 2024 | ||||||||
| Revenues based on customer’s location: | |||||||||
| United States | 3,209 | 3,747 | |||||||
| Europe | 1,336 | 1,169 | |||||||
| Asia - Pacific | 42 | 180 | |||||||
| Rest of the world | 447 | 187 | |||||||
| Total Revenues | $ | 5,034 | $ | 5,283 | |||||
| Three Months Ended | |||||||||
| March 31, | |||||||||
| Dollars in thousands, except per share data | 2025 | 2024 | |||||||
| GAAP net loss | $ | (4,834 | ) | $ | (6,276 | ) | |||
| Adjustments: | |||||||||
| Amortization of intangible assets | - | 831 | |||||||
| M&A transaction | - | (467 | ) | ||||||
| Integration/Rebranding costs | - | 236 | |||||||
| Remeasurement of earnout liability | - | (4 | ) | ||||||
| Stock-based compensation expenses | 220 | 381 | |||||||
| Non-GAAP net loss | $ | (4,614 | ) | $ | (5,299 | ) | |||
| Shares used in net loss per share | 10,486,151 | 8,590,088 | |||||||
| Non-GAAP net loss per share | $ | (0.44 | ) | $ | (0.62 | ) | |||
| Three Months Ended | |||||||||||||||
| March 31, | March 31, | ||||||||||||||
| 2025 | 2024 | ||||||||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | |||||||||||
| GAAP operating loss | $ | (4,853 | ) | (96.4 | )% | $ | (6,502 | ) | (123.1 | )% | |||||
| Amortization of intangible assets | - | - | 831 | 15.7 | % | ||||||||||
| M&A transaction | - | - | (467 | ) | (8.8 | )% | |||||||||
| Integration/Rebranding costs | - | - | 236 | 4.5 | % | ||||||||||
| Remeasurement of earnout liability | - | - | (4 | ) | (0.1 | )% | |||||||||
| Stock-based compensation expenses | 220 | 4.4 | % | 381 | 7.2 | % | |||||||||
| Non-GAAP operating loss | $ | (4,633 | ) | (92.0 | )% | $ | (5,525 | ) | (104.6 | )% | |||||
| Three Months Ended | |||||||||||||||
| March 31, | March 31, | ||||||||||||||
| 2025 | 2024 | ||||||||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | |||||||||||
| GAAP gross profit | $ | 2,122 | 42.2 | % | $ | 1,395 | 26.4 | % | |||||||
| Adjustments: | |||||||||||||||
| Amortization of intangible assets | - | - | 383 | 7.2 | % | ||||||||||
| Stock-based compensation expenses | 3 | 0.0 | % | 4 | 0.1 | % | |||||||||
| Non-GAAP gross profit | $ | 2,125 | 42.2 | % | $ | 1,782 | 33.7 | % | |||||||
| Three Months Ended | |||||||||||||||
| March 31, | March 31, | ||||||||||||||
| 2025 | 2024 | ||||||||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | |||||||||||
| GAAP research & development | $ | 918 | 18.2 | % | $ | 1,291 | 24.4 | % | |||||||
| Adjustments: | |||||||||||||||
| Stock-based compensation expenses | (36 | ) | (0.7 | )% | (46 | ) | (0.9 | )% | |||||||
| Non-GAAP research & development | $ | 882 | 17.5 | % | $ | 1,245 | 23.5 | % | |||||||
| Three Months Ended | |||||||||||||||
| March 31, | March 31, | ||||||||||||||
| 2025 | 2024 | ||||||||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | |||||||||||
| GAAP sales & marketing | $ | 3,837 | 76.2 | % | $ | 5,014 | 94.9 | % | |||||||
| Adjustments: | |||||||||||||||
| Amortization of intangible assets | - | - | (382 | ) | (7.2 | )% | |||||||||
| Integration/Rebranding costs | - | - | (193 | ) | (3.7 | )% | |||||||||
| Stock-based compensation expenses | (82 | ) | (1.6 | )% | (111 | ) | (2.1 | )% | |||||||
| Non-GAAP sales & marketing | $ | 3,755 | 74.6 | % | $ | 4,328 | 81.9 | % | |||||||
| Three Months Ended | |||||||||||||||
| March 31, | March 31, | ||||||||||||||
| 2025 | 2024 | ||||||||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | |||||||||||
| GAAP general & administrative | $ | 2,220 | 44.1 | % | $ | 1,592 | 30.1 | % | |||||||
| Adjustments: | |||||||||||||||
| M&A transaction | - | - | 467 | 8.8 | % | ||||||||||
| Amortization of intangible assets | - | - | (66 | ) | (1.2 | )% | |||||||||
| Integration/Rebranding costs | - | - | (43 | ) | (0.8 | )% | |||||||||
| Remeasurement of earnout liability | - | - | 4 | 0.1 | % | ||||||||||
| Stock-based compensation expenses | (99 | ) | (2.0 | )% | (220 | ) | (4.2 | )% | |||||||
| Non-GAAP general & administrative | $ | 2,121 | 42.1 | % | $ | 1,734 | 32.8 | % | |||||||
FAQ
What were Lifeward's (LFWD) Q1 2025 financial results?
How much did AlterG revenue grow for Lifeward (LFWD) in Q1 2025?
What is Lifeward's (LFWD) revenue guidance for 2025?
What major partnerships did Lifeward (LFWD) announce in Q1 2025?
What is Lifeward's (LFWD) cash position as of Q1 2025?
